(Q36775359)

16 August 2017

Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000-2008). (English)

1 reference

16 August 2017

0 references

1 reference

8

B Ljungberg

1 reference

16 August 2017

T Wahlgren

1

1 reference

16 August 2017

U Harmenberg

2

1 reference

16 August 2017

P Sandström

3

1 reference

16 August 2017

S Lundstam

4

1 reference

16 August 2017

J Kowalski

5

1 reference

16 August 2017

M Jakobsson

6

1 reference

16 August 2017

R Sandin

7

1 reference

16 August 2017

language of work or name

English

0 references

publication date

26 March 2013

1 reference

British Journal of Cancer

16 August 2017

1 reference

16 August 2017

108

1 reference

16 August 2017

7

1 reference

16 August 2017

1541-1549

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.2013.119

16 August 2017

0 references

cites work

Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629428

EAU guidelines on renal cell carcinoma: the 2010 update

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629428

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629428

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629428

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629428

The completeness of the Swedish Cancer Register: a sample survey for year 1998.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629428

Sorafenib in advanced clear-cell renal-cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629428

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629428

The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629428

Immunotherapy for advanced renal cell cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629428

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629428

Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629428

Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629428

The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629428

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629428

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629428

A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629428

Sex differences in renal cell cancer presentation and survival: an analysis of the National Cancer Database, 1993-2004.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629428

Impact of gender in renal cell carcinoma: an analysis of the SEER database

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629428

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629428

Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases

5 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2013.119

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/23531701

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.2013.119

1 reference

16 August 2017

1 reference

16 August 2017

PubMed publication ID

23531701

1 reference